SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Realignment of Bond Repayments

5 Nov 2018 07:00

RNS Number : 2667G
Collagen Solutions PLC
05 November 2018
 

5 November 2018

 

Collagen Solutions plc

("Collagen Solutions", the "Company" or the "Group")

 

Realignment of Bond Repayments to enable further growth to be achieved

Delivering on our Growth Strategy

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has entered into a deed of variation to its existing Bond Subscription Agreement with Norgine Ventures. This variation provides for a 6month principal repayment holiday. While there is no current year requirement for this variation, it will provide management with greater flexibility to exploit growth opportunities for future years.

 

Consistent with the Company's ability to conservatively manage its cash balances whilst looking to exploit growth opportunities for the benefit of shareholders the Company has agreed an amendment to the timing of principal repayments on Tranche A and Tranche B Bonds issued to Norgine Ventures under the 2017 Bond Subscription Agreement. The variation gives a principal repayment holiday of six months from 31st October 2018 to 31st March 2019 with the principal repayments being instead made via a balloon payment at the redemption of the Bonds on 30 September 2020 for Tranche A and 31 January 2021 for Tranche B. Prior to this agreement, the Company remained in compliance with all payment schedules and had repaid a total of £0.42million in principal against the total £3 million drawn.

 

Commenting on outlook, Hilary Spence, CFO says: "We have seen a return to growth in the first six months of the financial year and we remain on track to meet our financial performance objectives in line with market expectations. The management team has continued to generate a large number of business leads, some of which may require incremental upfront investment on initiation. Whilst there is no current financial year requirement, with one eye on exploiting opportunities for future financial years this variation provides management greater flexibility to deliver on these leads and on other growth opportunities that will contribute to future performance."

 

 

Enquiries:

Collagen Solutions Plc

 

Jamal Rushdy, CEO 

Via Walbrook

Hilary Spence, CFO

 

 

 

Cenkos Securities Plc (Nominated Adviser and Broker)

 

Steve Cox (Corporate Finance)

Tel: 0207 397 8900

Stephen Keys

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Helen Cresswell

Mob: 07841 917 679

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBBBDBISGBGIS
Date   Source Headline
10th Mar 20152:56 pmRNSDirector/PDMR Shareholding
10th Mar 20157:03 amRNSRegulatory Approvals for Collagen Solutions Client
10th Mar 20157:03 amRNSTrading Statement and Acquisition Update
9th Jan 20157:00 amRNSInvestor Presentation
7th Jan 20154:04 pmRNSHolding(s) in Company
7th Jan 20157:00 amRNSCEO Presents at OneMedForum
5th Jan 20157:00 amRNSContract signed with Globus Medical Inc.
22nd Dec 20147:00 amRNSNew contract to supply Desu Medical
17th Dec 201410:54 amRNSHolding(s) in Company
15th Dec 20147:00 amRNSContract signed with Kyeron
12th Dec 201410:50 amRNSHolding(s) in Company
10th Dec 20147:00 amRNSSouthern Lights Biomaterials Acquisition Completed
24th Nov 201411:48 amRNSGrant of Options
21st Nov 20147:30 amRNSSchedule 1 - Collagen Solutions Plc
21st Nov 20147:00 amRNSAcquisition
21st Nov 20147:00 amRNSChange of Adviser
21st Nov 20147:00 amRNSHalf Yearly Report
22nd Oct 201412:30 pmRNSHolding(s) in Company
17th Oct 20147:00 amRNSJellagen Collaboration
10th Sep 201412:23 pmRNSHolding(s) in Company
3rd Sep 20147:00 amRNSAppointment to Scientific Advisory Board
27th Aug 201411:52 amRNSResult of AGM
29th Jul 20143:19 pmRNSHolding(s) in Company
18th Jul 20147:00 amRNSPosting of Annual Report & Notice of AGM
10th Jul 20147:00 amRNSFinal Results
3rd Jul 20147:00 amRNSChange of Registered Office
10th Jun 20147:00 amRNSExclusive Licencing of Intellectual Property
19th May 20147:00 amRNSProfessor Robert Brown joins as Scientific Adviser
15th May 20147:00 amRNSExcellagen® enters new clinical trial
26th Mar 201410:48 amRNSHolding(s) in Company
3rd Mar 20147:00 amRNSAppointment of Director
27th Dec 201312:25 pmRNSDirector Shareholding
27th Dec 201311:58 amRNSResult of GM
17th Dec 201310:00 amRNSAnnouncement by Cardium Therapeutics
16th Dec 20139:03 amRNSSchedule 1 - Healthcare Investment Opportunities
10th Dec 20137:00 amRNSProposed acquisition
10th Dec 20137:00 amRNSHalf Yearly Report
19th Aug 201311:06 amRNSHolding(s) in Company
1st Aug 20131:43 pmRNSHolding(s) in Company
2nd May 201312:00 pmRNSHolding(s) in Company
22nd Apr 201312:19 pmRNSHolding(s) in Company
9th Apr 201310:57 amRNSHolding in Company
8th Apr 20135:41 pmRNSHolding(s) in Company
5th Apr 20137:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.